| abstract |
FIELD: medicine.SUBSTANCE: use of a combination of an antibody to PD-1 and a VEGFR inhibitor is proposed for the production of a drug for the treatment of malignant neoplasm, where the VEGFR inhibitor is apatinib or its pharmaceutically acceptable salt. A variable region of a light chain of the antibody to PD-1 contains a hypervariable section 1 of the light chain (LCDR1), LCDR2 and LCDR3, which are shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively, and the variable region of a heavy chain of the antibody to PD-1 contains a hypervariable section 1 of the heavy chain (HCDR1), HCDR2 and HCDR3, which are shown in SEQ ID NO:1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively. A method for attenuating an adverse effect caused by the antibody to PD-1 and the VEGFR inhibitor, and a method for reducing a dose of the antibody to PD-1 and the VEGFR inhibitor injected separately are also proposed. A pharmaceutical kit for the treatment of tumor/cancer containing the above-mentioned VEGFR inhibitor and antibody to PD-1 is also proposed.EFFECT: inventions are effective in the treatment of malignant neoplasm, and also reduce the occurrence of hemangioma-associated adverse effect in the treatment of malignant tumors.15 cl, 3 dwg, 5 tbl, 3 ex |